Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence.

摘要: Chronic kidney disease (CKD) is associated with very high mortality rates, mainly of cardiovascular origin. The retention phosphate (P) and increased fibroblast growth factor-23 levels are common, even at early stages CKD, due to disturbances in normal P homeostasis. Later, hyperphosphatemia appears, which has also been strongly rates linked P-mediated procalcifying effects. Treatment guidelines for these patients continue be poorly implemented, least partially the lack adherence a P-restricted diet P-binder therapy. Calcium-free binders, such as lanthanum carbonate, have decreased progression vascular calcification, rendering them an important therapeutic alternative risk CKD patients. Lanthanum carbonate typically available chewable tablets, new presentation oral powder may provide useful armamentarium. This tasteless, odorless, colorless semisolid compound miscible food. In recent study healthy individuals, safety efficacy this novel form were evaluated, it was concluded that well tolerated pharmacodynamically equivalent form. long run, individualization preferences treatments seems achievable goal prior final demonstration improvements hard outcomes wide clinical trials